BRPI1011206A2 - administração contínua de ligantes de integrina para tratar câncer - Google Patents

administração contínua de ligantes de integrina para tratar câncer

Info

Publication number
BRPI1011206A2
BRPI1011206A2 BRPI1011206A BRPI1011206A BRPI1011206A2 BR PI1011206 A2 BRPI1011206 A2 BR PI1011206A2 BR PI1011206 A BRPI1011206 A BR PI1011206A BR PI1011206 A BRPI1011206 A BR PI1011206A BR PI1011206 A2 BRPI1011206 A2 BR PI1011206A2
Authority
BR
Brazil
Prior art keywords
treat cancer
continuous administration
integrin ligands
integrin
ligands
Prior art date
Application number
BRPI1011206A
Other languages
English (en)
Inventor
Elizabeth Cohen-Jonathan Moyal
Martin Andreas Picard
Matthias Dotzauer
Ullrich Bethe
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43223150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1011206(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI1011206A2 publication Critical patent/BRPI1011206A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI1011206A 2009-05-25 2010-05-25 administração contínua de ligantes de integrina para tratar câncer BRPI1011206A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09006941 2009-05-25
PCT/EP2010/003162 WO2010136168A2 (en) 2009-05-25 2010-05-25 Continuous administration of integrin ligands for treating cancer

Publications (1)

Publication Number Publication Date
BRPI1011206A2 true BRPI1011206A2 (pt) 2016-03-15

Family

ID=43223150

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011206A BRPI1011206A2 (pt) 2009-05-25 2010-05-25 administração contínua de ligantes de integrina para tratar câncer

Country Status (16)

Country Link
US (1) US20120130146A1 (pt)
EP (1) EP2445534A2 (pt)
JP (1) JP2012528079A (pt)
KR (1) KR20120104491A (pt)
CN (1) CN102448497A (pt)
AU (1) AU2010252280A1 (pt)
BR (1) BRPI1011206A2 (pt)
CA (1) CA2763275A1 (pt)
CL (1) CL2011002962A1 (pt)
EA (1) EA201101651A1 (pt)
EC (1) ECSP11011552A (pt)
IL (1) IL216537A0 (pt)
MX (1) MX2011012491A (pt)
NZ (1) NZ597339A (pt)
SG (1) SG176103A1 (pt)
WO (1) WO2010136168A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012007137A1 (en) * 2010-07-16 2012-01-19 Merck Patent Gmbh Peptide for use in the treatment of breast cancer and/or bone metastases
EP3494974B1 (en) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
KR20140103122A (ko) 2011-11-17 2014-08-25 넨키 인스티튜트 오브 익스페리멘탈 바이올로지 신경교종을 치료하기 위한 조성물 및 방법
KR101470700B1 (ko) * 2011-11-25 2014-12-12 서울대학교산학협력단 표적 항암제의 내성 극복 방법
KR101964169B1 (ko) * 2014-04-04 2019-04-01 다이호야쿠힌고교 가부시키가이샤 항종양성 백금 착체를 함유하는 항종양제 및 항종양 효과 증강제
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
US10206871B2 (en) * 2014-10-14 2019-02-19 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
CN109310702A (zh) 2016-05-20 2019-02-05 芝加哥大学 用于化学疗法、靶向疗法、光动力疗法、免疫疗法和它们的任何组合的纳米颗粒
CN111032157B (zh) * 2017-06-29 2023-04-21 医视特有限公司 基于模拟的药物治疗计划
WO2019028250A1 (en) 2017-08-02 2019-02-07 The University Of Chicago NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4517686A (en) 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4614517A (en) 1982-08-04 1986-09-30 La Jolla Cancer Research Foundation Tetrapeptide
US4661111A (en) 1982-08-04 1987-04-28 La Jolla Cancer Research Foundation Polypeptide
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
CA2097060A1 (en) 1990-12-04 1992-06-05 Peter J. Curtis Bifunctional antibodies and method of preparing same
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5407804A (en) 1992-05-22 1995-04-18 Applied Genetics Inc. Assays for O6 -methylguanine-DNA methyltransferase
GB9224888D0 (en) 1992-11-27 1993-01-13 Univ Singapore Monoclonal antibody
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
ATE227567T1 (de) 1994-05-27 2002-11-15 Merck & Co Inc Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
ZA955391B (en) 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
WO1996000730A1 (en) 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
IT1271688B (it) 1994-08-04 1997-06-04 Menarini Ricerche Sud Spa Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche
JPH10504825A (ja) 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション 二環式化合物
WO1996026190A1 (en) 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
SI0910563T1 (en) 1995-06-29 2003-10-31 Smithkline Beecham Corporation Integrin receptor antagonists
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
CN1209744A (zh) 1995-12-29 1999-03-03 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
TR199801255T2 (xx) 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronektin resept�r antagonistleri.
WO1997024124A1 (en) 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
EA002271B1 (ru) 1996-03-20 2002-02-28 Хехст Марион Руссель ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ В ОТНОШЕНИИ ИНТЕГРИНОВ, В ЧАСТНОСТИ В ОТНОШЕНИИ ИНТЕГРИНА АЛЬФАvБЕТА 3, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, ИСПОЛЬЗУЕМЫЕ В ЭТОМ СПОСОБЕ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МЕДИКАМЕНТОВ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
ES2185009T3 (es) 1996-04-10 2003-04-16 Merck & Co Inc Antagonistas de alfa y beta 3'.
US5925655A (en) 1996-04-10 1999-07-20 Merck & Co., Inc. αv β3 antagonists
AU2438297A (en) 1996-05-09 1997-11-26 Alcon Laboratories, Inc. Combinations of angiostatic compounds
CN1226254A (zh) 1996-05-31 1999-08-18 斯克里普斯研究学院 用于抑制αV、β5介导的血管发生的方法和组合物
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
JP2002511052A (ja) 1996-08-29 2002-04-09 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
US5981546A (en) 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
EP0946180A4 (en) 1996-10-07 2003-07-23 Smithkline Beecham Corp METHODS FOR STIMULATING BONE FORMATION
CA2268940A1 (en) 1996-10-30 1998-05-07 Merck & Co., Inc. Integrin antagonists
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
JP2001504456A (ja) 1996-10-30 2001-04-03 メルク エンド カンパニー インコーポレーテッド インテグリン拮抗薬
CA2272090A1 (en) 1996-12-09 1998-06-18 Matthew J. Fisher Integrin antagonists
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653645A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
CO4920232A1 (es) 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
CA2277273C (en) 1997-01-17 2008-03-25 Merck & Co., Inc. Integrin antagonists
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6239138B1 (en) 1997-07-25 2001-05-29 Smithkline Beecham Corporation Vitronectin receptor antagonist
WO1999006049A1 (en) 1997-08-04 1999-02-11 Smithkline Beecham Corporation Integrin receptor antagonists
WO1999011626A1 (en) 1997-09-04 1999-03-11 Smithkline Beecham Corporation Integrin receptor antagonists
PE122699A1 (es) 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
FR2768734B1 (fr) 1997-09-24 2000-01-28 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
IL135189A0 (en) 1997-09-24 2001-05-20 Smithkline Beecham Corp Vitronectin receptor antagonist
FR2768736B1 (fr) 1997-09-24 2000-05-26 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
JP2002500162A (ja) 1997-09-24 2002-01-08 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
SK9192000A3 (en) 1997-12-17 2001-03-12 Merck & Co Inc Integrin receptor antagonists
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
ES2243016T3 (es) 1997-12-17 2005-11-16 MERCK & CO., INC. Antagonistas de receptores de integrinas.
EP1047425A4 (en) 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
DE69830806T2 (de) 1997-12-17 2006-04-27 Merck & Co., Inc. Integrinrezeptor antagonisten
CN1168741C (zh) 1998-01-23 2004-09-29 默克专利股份有限公司 抗αv整联蛋白单克隆抗体及其在抑制αvβ6整联蛋白与纤连蛋白附着中的应用
WO2000006169A1 (en) 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
AU748621B2 (en) 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
WO2000038715A2 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
DE60035779T2 (de) 1999-06-02 2008-04-30 Merck & Co., Inc. Alpha v integrin-rezeptor antagonisten
EP1328656A4 (en) 2000-09-29 2005-09-14 Univ Johns Hopkins Med METHOD OF PREDICTING CLINICAL REACTION TO CHEMOTHERAPEUTIC TREATMENT WITH ALKYLATING AGENTS
CN101370522A (zh) * 2006-01-18 2009-02-18 默克专利有限公司 使用整联蛋白配体治疗癌症的特别疗法
EA017864B1 (ru) * 2007-01-18 2013-03-29 Мерк Патент Гмбх Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака

Also Published As

Publication number Publication date
NZ597339A (en) 2013-10-25
US20120130146A1 (en) 2012-05-24
CN102448497A (zh) 2012-05-09
SG176103A1 (en) 2011-12-29
WO2010136168A2 (en) 2010-12-02
AU2010252280A1 (en) 2012-01-19
WO2010136168A8 (en) 2011-09-22
CA2763275A1 (en) 2010-12-02
JP2012528079A (ja) 2012-11-12
IL216537A0 (en) 2012-02-29
WO2010136168A3 (en) 2011-07-07
KR20120104491A (ko) 2012-09-21
EP2445534A2 (en) 2012-05-02
MX2011012491A (es) 2011-12-14
ECSP11011552A (es) 2012-01-31
EA201101651A1 (ru) 2012-08-30
CL2011002962A1 (es) 2012-06-01

Similar Documents

Publication Publication Date Title
BR112013011730A2 (pt) composição de oligossacarídeos para tratar doenças da pele
HUE048876T2 (hu) Rákos megbetegedések kezelése
IL228538A0 (en) Methods for increasing efficacy of folr1 cancer therapy
PL2739153T3 (pl) Leczenie raka sutka
ES2638522T8 (es) Procedimientos para detectar cáncer
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
PT2768493T (pt) Fitocanabinoides para utilização no tratamento do cancro da mama
IL224370B (en) Combination treatment for prostate carcinoma
PT2829881T (pt) Diagnóstico para cancro colo-rectal
PL2552438T3 (pl) Sposoby leczenia raka wątrobowokomórkowego
HUE046667T2 (hu) Rák kombinatív kezelése
EP2790736A4 (en) IN VIVO ADMINISTRATION OF OLIGONUCLEOTIDES
BR112014005091A2 (pt) composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
PL2435825T3 (pl) Sposoby leczenia chorób
IL216537A0 (en) Continuous administration of integrin ligands for treating cancer
IL228430A0 (en) Cancer treatment
IL226246A0 (en) Methods of treating cancer
SMT201700056B (it) Fosfaplatine e relativo utilizzo per il trattamento di cancro
PL2400973T3 (pl) Identyfikacja zewnątrzkomórkowej postaci PTEN, która może być zastosowana do leczenia raka
PT2405748T (pt) Administração de ibuprofeno intravenoso
BRPI1009435A2 (pt) tratamento para câncer no pâncreas
HUE037212T2 (hu) Anti-alfa-V integrin ellenanyag prosztatarák kezelésére
PL2734199T3 (pl) Syntetyczna letalność i leczenie nowotworów
EP2522366A4 (en) OBJECTIVE FOR TUMOR PLACES
PT2467140T (pt) Lapatinib para tratamento do cancro

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]